FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 254 filers reported holding FATE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $159,593 | -88.3% | 42,672 | -85.2% | 0.00% | – |
| Q2 2023 | $1,369,319 | -74.8% | 287,672 | -69.9% | 0.00% | -100.0% |
| Q1 2023 | $5,440,872 | -33.0% | 954,539 | +18.6% | 0.00% | -50.0% |
| Q4 2022 | $8,119,847 | -48.6% | 804,742 | +14.1% | 0.00% | -50.0% |
| Q3 2022 | $15,799,364 | -9.6% | 705,014 | 0.0% | 0.00% | -20.0% |
| Q2 2022 | $17,470,247 | -19.3% | 705,014 | +26.2% | 0.01% | 0.0% |
| Q1 2022 | $21,658,008 | -53.1% | 558,628 | -29.2% | 0.01% | -44.4% |
| Q4 2021 | $46,191,000 | +2.0% | 789,454 | +3.4% | 0.01% | -10.0% |
| Q3 2021 | $45,272,000 | -28.3% | 763,829 | +5.0% | 0.01% | -28.6% |
| Q2 2021 | $63,145,000 | -6.6% | 727,557 | -11.3% | 0.01% | -6.7% |
| Q1 2021 | $67,642,000 | -11.5% | 820,405 | -2.4% | 0.02% | -16.7% |
| Q4 2020 | $76,446,000 | +118.9% | 840,713 | -3.8% | 0.02% | +100.0% |
| Q3 2020 | $34,930,000 | +1113.3% | 873,914 | +941.6% | 0.01% | +800.0% |
| Q2 2020 | $2,879,000 | – | 83,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $197,709,000 | 22.51% |
| Redmile Group, LLC | 12,957,222 | $758,127,000 | 17.24% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $60,690,000 | 6.28% |
| Casdin Capital, LLC | 3,400,000 | $198,934,000 | 5.61% |
| Ally Bridge Group (NY) LLC | 270,000 | $15,798,000 | 5.52% |
| DAFNA Capital Management LLC | 372,160 | $21,775,000 | 5.48% |
| Tri Locum Partners LP | 142,032 | $8,310,000 | 3.27% |
| Kynam Capital Management, LP | 95,561 | $5,591,000 | 2.99% |
| Artal Group S.A. | 1,800,000 | $105,318,000 | 2.86% |
| Bellevue Group AG | 3,775,736 | $220,918,000 | 2.28% |